Strategies for next-generation immunotherapy success

Early-stage cancer biotech leaders and Allucent, a global contract research organization, gathered for a Citeline roundtable to discuss how the industry can advance the development of next-generation immunotherapies for use in solid tumors. Capture the key takeaways from their conversation, in this illuminating executive summary.

Read now for executive perspectives on:

• Why progress of immunotherapies for solid tumors has been challenging and what is needed to move forward
• Lessons learned from hematologic malignancy trials
• Tactics for reducing risk in solid tumor trials
• Strategies for improving CAR T-cell infiltration and function within the suppressive tumor microenvironment
• Accelerating development with early regulatory engagement
• Critical success factors for advancing next-generation immunotherapies such as CAR T, TCR-T, and bispecific antibodies